Journal of Oncology Pharmacy Practice

Article	Citations
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings	55
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class	38
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors	28
Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department	26
Cancer patient experience of telephone clinics implemented in light of COVID-19	25
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide	24
Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results	19
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab	18
ISOPP Standards for the Safe Handling of Cytotoxics	17
Factors affecting health-related quality of life among prostate cancer patients: A systematic review	17
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial	16
Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature	15
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations	15
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab	15
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases	14
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone	14
Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?	14
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab	13
Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review	13
The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer	13
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review	13
Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations	12
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature	12
Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East	12
Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective co	12

A real-world data approach to determine the optimal dosing strategy for pembrolizumab	12
New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature	11
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab	11
Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study	11
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer	11
Impact of pharmacist-managed immune checkpoint inhibitor toxicities	11
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis	11
Impact of clinical pharmacy in oncology and hematology centers: A systematic review	10
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care	10
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients wit	10
Management of skin adverse reactions in oncology	10
Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia	10
Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program	10
Safety of ninety-minute daratumumab infusion	10
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review	10
Thyroid cancer risk factors and Pakistani University students’ awareness towards its preventive practice	9
Larotrectinib followed by selitrectinib in a novelDCTN1–NTRK1fusion undifferentiated pleomorphic sarcoma	9
Global oncology pharmacy response to COVID-19 pandemic: Medication access and safety	9
Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease	9
Applications and challenges in therapeutic drug monitoring of cancer treatment: A review	9
Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors	9
Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration	9
Lorlatinib induced proteinuria: A case report	8
Severe rhabdomyolysis induced by possible drug–drug interaction between Ribociclib and Simvastatin	8
Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review	8
A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care	8
Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors	8
A new treatment of alopecia induced by palbociclib: Topical cetirizine	8
Anticancer agents and phytotherapy: Interactions that are often unrecognized	8
Occupational exposure assessment in professionals who manipulate and administer antineoplastic drugs in a university hospital in Southern Brazil	8
Routine antiemetic prophylaxis with dexamethasone during COVID-19: Should oncologists reconsider?	8
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine	8
Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation	8
Temozolomide-induced aplastic anaemia: Case report and review of the literature	8
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy	8
Medication discrepancies in hospitalized cancer patients: Do we need medication reconciliation?	8
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma	8
Impact of clinical pharmacy services in a hematology/oncology ward in Morocco	8
Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team	8
ISOPP 2023 – Abstract Book	8
Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis	7
Assessment of Canadian patient education material for oncology pharmaceutics	7
Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature	7
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study	7
Use of active learning and simulation to teach pharmacy students order verification and patient education best practices with oral oncolytic therapies	7
Nivolumab treatment for metastatic thymic epithelial tumors	7
Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report	7
Ambulatory chemotherapy: Past, present, and future	7
Ribociclib induced acute kidney injury: A case report	7
The safe handling of chemotherapy drugs in low- and middle-income countries: An overview of practices	7

Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy	7
Knowledge, attitude, preventive practices and perceived barriers to screening about colorectal cancer among university students of newly merged district, Kpk, Pakistan – A cross-sectional study	7
Blood contamination of the pharmaceutical staff by irinotecan and its two major metabolites inside and outside a compounding unit	7
Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics	7
Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab	7
The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma	7
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study	7
Global changes to the chemotherapy service during the covid-19 pandemic	7
Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer	6
Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT)	6
Increasing pharmacy productivity and reducing medication turnaround times in an Italian comprehensive cancer center by implementing robotic chemotherapy drugs compounding	6
Bluish-gray fingernail discoloration due to the use of nivolumab	6
Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: A hospital-based retrospective cross-sectional s	6
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma	6
Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma	6
Non-pharmacological integrative therapies for chronic cancer pain	6
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff	6
Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?	6
Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma	6
Evaluation of methotrexate clearance with an enteral urine alkalinization protocol for patients receiving high-dose methotrexate	6
Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer	6
Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies	6
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City	6
Case report on 5-fluorouracil induced cerebrovascular accident	6
A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population	6
Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology–oncology and transplant clinic: Assessment and significance	6
Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports	6
Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma	6
Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)	6
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease	6
Quantification of healthcare workers’ exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study	6
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer	6
Ifosfamide induced encephalopathy in a child with osteosarcoma	6
Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum	6
Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer	6
Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient	6
Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital	6
Impact of clinical pharmacists in an inpatient medical oncology service: A prospective study at a comprehensive cancer center in Jordan	6
A clinical approach to non-neutropenic fever in children with cancer	6
Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151	6
Advanced papillary thyroid carcinoma responding to nivolumab	6
Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners	6
Dosing errors in total parenteral nutrition prescriptions at a specialized cancer care hospital of Lahore: The role of clinical pharmacist	6
Cyto-SAT: A self-assessment tool for the safe handling of cytotoxic drugs adapted for use in low- and middle-income countries	5
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma	5
International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care	5
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature	5
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia	5
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report	5
Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic co	5
The efficacy and safety of alpelisib in breast cancer: A real-world analysis	5
Central diabetes insipidus induced by temozolomide: A report of two cases	5
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma	5
Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey	5
Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States:	5
Fatal hepatitis B reactivation in a patient receiving chemoradiation for cervical cancer	5
Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges	5
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program	5
Abstracts	5
Case of metastatic kaposi sarcoma successfully treated with anti-PD-1 immunotherapy	5
A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis	5
Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy	5
Glioblastoma and bevacizumab in elderly patients: Monocentric study	5
Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation	5
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?	5
Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia	5
Barriers and facilitators for the safe handling of antineoplastic drugs	5
Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine	5
Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure	5
Evaluation of a patient self-medication program in allogeneic hematopoietic stem cell transplantation	5
Awareness is the first step: What Ghanaian community pharmacists know about cancer	5
Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature	5
Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold	5
A rare case of gastric cancer with bilateral breast metastasis during pregnancy	5
Trousseau’s syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab	5
Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials	5
Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction	5
Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash	5
Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients	5
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma	5

Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient	5
Sustained erythrocytosis due to the use of Lenvatinib	5
Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting	5
Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report	5
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature	5
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization	5
Hypertriglyceridemia induced by S-1: A novel case report and review of the literature	5
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma	5
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?	5
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma	5
Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review	5
Patterns of complementary and alternative medicine use among Tunisian cancer patients	5
Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital	5
Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant	5
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study	5
Anaphylaxis related to disinfection with chlorhexidine in a teenager treated for cancer	4
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma	4
Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia	4
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion	4
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions	4
A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?	4
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	4
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report	4
Fluconazole-Induced adrenal insufficiency following allogeneic hematopoietic cell transplant	4
Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report	4
Development of carpal tunnel syndrome in association with checkpoint inhibitors	4
Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer	4
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant	4
Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis	4
Novel agents for myelodysplastic syndromes	4
Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction usin	4
Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience	4
Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman	4
Veliparib for the treatment of solid malignancies	4
Unmet supportive care needs and predictor of breast cancer patients in Bangladesh: A cross-sectional study	4
Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer	4
Tyrosine kinase inhibitors and COVID-19	4
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review	4
Risk reduction in a cancer chemotherapy production unit: Contribution of an automated drug dispensing system	4
A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners	4
Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma	4
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma	4
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab	4
Educational needs of oncology pharmacists: A survey by the International Society of Oncology Pharmacy Practitioners	4
Suggestion of Tunisia’s medical oncologist in the management of breast cancer during COVID-19 pandemic	4
Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019	4
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	4
The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer	4
Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia	4
Proposal of a simple and rapid method for the chemotherapy preparations analytical control by spectrophotometry UV-Vis method	4
Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy	4
Clinical pharmacy in onco-hematology and bone marrow transplant: A valuable contribution to improving patient safety	4
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia	4
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metab	4
Unmet supportive care needs and determinants among cancer patients treated at University of Gondar Specialized Hospital, Northwest Ethiopia: A prospective cross-sectional study	4
Preservation of cognitive function after brain irradiation	4
Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review	4
A pharmacist’s review of the treatment of systemic light chain amyloidosis	4
Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards	4
Gilteritinib administration in a hemodialysis patient	4
Vascular endothelial growth factor inhibitor induced hypertension: Retrospective analysis of the impact of blood pressure elevations on outcomes	4
Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case	4
Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients’ online forums	4
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies	4
Clinical pharmacy services in an ambulatory oncology clinic: Patient perception and satisfaction	4
Capecitabine induced Steven–Johnson syndrome: A rare case report	4
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	4
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists	4
Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review	4
Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia	4
Tamoxifen-induced acute mania: A case report	4
Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report	4
Pemetrexed-induced Sweet Syndrome: First case report in the medical literature	4
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer	4
Consensus Recommendations for the Safe Handling of Cytotoxic Agents in Cytotoxic Academic Research Laboratories (CARL)	3
A study to assess the impact of pharmaceutical care services to cancer patients in a tertiary care hospital	3
Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator	3
Managing chemotherapy-related toxicities in the community setting: A survey of pharmacists in Ontario	3
The role of ado-trastuzumab emtansine in current clinical practice	3
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis	3
Perspectives toward biosimilars among oncologists: A Malaysian survey	3
Atezolizumab-induced hemolytic anemia – A case report	3
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	3
Oncology boot camp: A preparatory curriculum for advanced pharmacy practice experience students	3
Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology	3
Cost analysis of daratumumab therapy: Is there a cost benefit to using the recently approved subcutaneous product versus the IV product?	3
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with aDPYDvariant and decreased dihydropyrimidine dehydrogenase enzyme activity	3
Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma	3
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies	3
Acceptance of coronavirus disease 2019 vaccination by cancer patients in Cyprus: A cross-sectional study	3
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer	3
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?	3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	3
Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis	3
Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault	3